Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease

Klatte, Derk C.F.; Gasparini, Alessandro; Xu, Hong; Deco, Pietro de; Trevisan, Marco; Johansson, Anna L.V.; Wettermark, Björn; Ärnlöv, Johan; Janmaat, Cynthia; Lindholm, Bengt; Dekker, Friedo W.; Coresh, Josef; Carrero, Juan Jesús

doi:10.1053/j.gastro.2017.05.046

Cited by 143 publications

(152 citation statements)

References 47 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…Among the included articles 22,17,[23][24][25] Lazarus et al 17 has included two cohorts in his article namely Atherosclerosis Risk in Communities (ARIC) study and Geisinger Health System Replication Cohort (GHSRC) study. Hence, we considered four cohort studies and two case-control studies for inclusion with 720758 patients from cohort and 84078 patients from the casecontrol study.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…Hence, we considered four cohort studies and two case-control studies for inclusion with 720758 patients from cohort and 84078 patients from the casecontrol study. Studies were from the USA, 22,17,24 Taiwan, 23 and Sweden 25 . All the studies published in the year 2016 except by Klatte et al 25 The follow-up period among studies ranged from 5-13.9 years.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies

Hussain

Singh²,

Habib

et al. 2019

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies

Hussain

Singh²,

Habib

et al. 2019

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

“…PPIs are generally considered safe; however, several studies have reported a number of adverse side effects after long‐term use. These include bone fracture, enteric infection, pneumonia, myocardial infarction, stroke, dementia, chronic kidney disease, micronutrient deficiencies, and even malignancies . Nonetheless, many of the reported safety issues pertaining to PPI use have been based on observational studies that used databases which were not specific to these issues and were prone to potential biases.…”

mentioning

confidence: 99%

“…chronic kidney disease, (10) micronutrient deficiencies, (11) and even malignancies. (12)(13)(14)(15)(16)(17)(18) Nonetheless, many of the reported safety issues pertaining to PPI use have been based on observational studies that used databases which were not specific to these issues and were prone to potential biases.…”

mentioning

confidence: 99%

Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C

Kao

Tan

et al. 2019

Hepatology

View full text Add to dashboard Cite

Researchers have hypothesized that the long-term use of proton pump inhibitors (PPIs) can increase the risk of developing cancer. However, the association between PPI use and hepatocellular carcinoma (HCC) risk is unclear. Using data from the Taiwan National Health Insurance Research Database for the period between 2003 and 2013, we identified 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. One-to-one propensity score matching by gender, age, cohort entry year, comorbidity, and medication resulted in the inclusion of 7,492 pair of patients (PPI users and non-PPI users) for analyses. We performed multivariate and stratified analysis using the Kaplan-Meier method and Cox proportional hazards models in order to estimate the association between PPIs use and the risk of developing HCC. In the HBV cohort, 237 patients developed HCC during a median follow-up of 53 months. However, PPI use was not associated with an increased HCC in the risk of developing HCC (adjusted hazard ratio aHR, 1.25; 95% confidence interval CI, 0.90-1.73; p=0.18). In the HCV cohort, 211 patients developed HCC, but again, PPI use was not associated with an increase in the risk of developing HCC (aHR, 1.19; 95% CI, 0.88-1.61; p=0.25). We observed no relationship between dose-dependent effect of PPI use and HCC risk. Subgroup analysis also confirmed PPI use was not correlated to an increased HCC risk. Conclusions Based on a retrospective, nationwide population-based cohort study in Taiwan, where the prescription of PPI is tightly regulated, PPI use is not associated with the risk of developing HCC among patients with chronic HBV or HCV infections. This article is protected by copyright. All rights reserved.

show abstract

“…26). An increasing cumulative PPI use was associated with a higher risk for both primary outcome [23] . 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 9 Cardiovascular events have also been associated with PPIs.…”

Section: Introductionmentioning

confidence: 91%

Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis

et al. 2018

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs. Even if PPI are usually considered as safe, there is a growing concern for a range of adverse effects of chronic PPI therapy often in the absence of appropriate indications. We propose, after a summary of renal, cardiovascular and neurological complications (dementia, chronic kidney disease, myocardial infarction and stroke), an integrative overview of the potential biological mechanisms involved. Eleven positive pharmacoepidemiological studies, mainly based on health insurance database linkage to hospital database, reported an increased risk of complications associated to PPI use and often a graded association suggesting also a possible dose-response relationship. Several mechanisms have been suggested through in vitro studies (endothelial dysfunction, endothelial senescence, hypomagnesemia, increase of chromogranin A levels, decrease of nitric oxide in endothelial cells) leading to the impairment of vascular homesostasis, paving the way to these complications. Evidence that PPIs may have off-targets and pleiotropic effects are mounting and may impose a cautious attitude in the prescription of PPI's, especially in elderly and/or in the context of chronic use.

show abstract

Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease

Abstract: Initiation of PPI therapy and cumulative PPI exposure is associate with increased risk of CKD progression in a large, North European healthcare system. Although consistent, the association was modest in magnitude, and cannot exclude residual confounding.

Cited by 143 publications

References 47 publications

Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies

Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies

Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C

Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis

Contact Info

Product

Resources

About